Current Studies/Clinical Trials

Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

Description: The study is designed to examine the efficacy and safety of escitalopram in combination with a psychosocial intervention (PSI) as treatment for agitation in AD patients.

Study Length:  6 months

Study Requirements:

  • Diagnosis of Alzheimer’s disease with significant agitation/aggression
  • A study partner who will accompany you to all study visits

Contact:
Patricia Henderson 412-692-2703 or hendersonpl@upmc.edu or
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

 


Sleep Study (Prefrontal Cortex Stimulation in MCI)

Description: Previous research has shown that certain forms of brain stimulation can affect sleep patterns as well as cognitive function. The goal of this study is to test whether changes in sleep patterns with brain stimulation influence cognition in people with Mild Cognitive Impairment (MCI).

Study Length:  14 days

Study Requirements:

  • Diagnosis of Mild Cognitive Impairment (MCI)
  • Age 60-85
  • Normal or corrected-to-normal visual and auditory acuity

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

 


Dementia with Lewy Bodies Consortium

Description: The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers improve the diagnosis, care, and treatment of patients with this disease.

Study Length:  5 years

Study Requirements:

  • Age 40-90
  • Diagnosis of Lewy Body Dementia (DLB) or high likelihood
  • A study partner who will accompany you to all study visits

Contact: 
Donna Simpson at 412-692-2717 or simpsondm@upmc.edu or
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

 


Alzheimer’s Disease Neuroimaging Initiative – 3 (ADNI3)

Description: The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection. For more information about the ADNI3 study visit http://www.adni-info.org/

Study Length:  up to 5 years

Study Requirements:

  • 55-90 years of age
  • Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
  • A study partner who will accompany you to all study visits

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

 


The Rhythm Experience and African Culture Trial (REACT!)

Description: REACT! Is an Alzheimer’s Association-funded study and will compare two activities, African Dance and an Education/Discussion Group, which might be beneficial for older African Americans aged 65-75.

Study Length:  Six months

Study Requirements: Africans Americans aged 65-75

Contact:
Mariegold Wollam, Project coordinator at 412-302-6679 or visit: www.med.upenn.edu/aging/react.html

 


Lithium As a Treatment to prevent Impairment of Cognition in Elders (LATTICE)

Description: The purpose of this study is to examine the potential disease modifying properties of lithium in individuals with mild cognitive impairment (MCI). For additional information visit: youtu.be/vcNBr6QSp4w

Study Length:  2 years

Study Requirements

  • Age 60 years or older
  • Diagnosis mild cognitive impairment

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu

 


Connectomes in Brain Aging

Description: This study will determine how different parts of the brain are connected and how these connections allow people to think, behave and feel. The study will involve 2-3 days of scanning and tests.  Some people will be asked to return after two years.

Study Length: 2-3 days and for some two years

Study Requirements

  • 50-89 years of age
  • Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease.

Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu or
Rebecca Roush 412-586-9860

 

Share This:
FacebookTwitterGoogle+Email